Should you buy today’s biggest winner or biggest loser?

These two stocks are among today’s biggest movers, but are they worth buying?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Clinical stage biopharmaceutical company Motif Bio (LSE: MTFB) has slumped by as much as 21% today after announcing the postponement of its proposed public offering of American Depositary Shares (ADSs) on the NASDAQ Global Market. However, the company intends to continue to engage with investors and will provide a further update to the market in due course.

Motif Bio had intended to raise up to $60m from the move to fund its flagship drug iclaprim’s phase III clinical trials. Although today’s news doesn’t necessarily mean that funding will be lacking for the potential new treatment, it has caused investor sentiment towards Motif Bio to come under severe pressure. However, with the company stating that today’s move is a deferral, it could be a case of an overreaction by the market.

Still, Motif Bio is likely to remain highly volatile in the short run owing to doubts surrounding its near-term strategy. Therefore, it may be prudent for investors to watch, rather than buy, the company at the present time.

Certainly, it has significant long-term potential and the multi-drug-resistant bacteria space is set to be a major growth area as ‘superbugs’ are emerging at a faster pace than new antibiotics are being developed. And with Motif Bio having an experienced management team and a sound strategy to build its treatment pipeline, its shares could continue to rise over the long term following their 20% gain since the start of the year. However, until more clarity is forthcoming regarding its public offering, it may be a good idea to look elsewhere for healthcare investments.

Value for money

While Motif Bio is among today’s major fallers, STM Group (LSE: STM) is among the biggest winners. STM’s shares are up by as much as 16% following the release of an update that shows the cross-border financial services provider has seen its new business numbers increase by 28% in July.

This follows an adjustment to STM’s pricing strategy for its core product, QROPS, with this being done to stimulate and drive new business growth for the benefit of future recurring revenue. And with new business applications in July representing the highest month of applications over the last year and a 75% uplift on the average number of applications of the first four months of the year, the pricing adjustment seems to be having its intended result.

Looking ahead, STM is forecast to increase its earnings by 23% in the current year and by a further 33% next year. This has the potential to act as a further positive catalyst on its share price and with STM trading on a price-to-earnings (P/E) ratio of just 8.2, it seems to offer good value for money for less risk-averse investors.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

Will the BP share price go gangbusters under President Trump?

The BP share price has had a rough ride lately and Harvey Jones says the FTSE 100 oil giant looks…

Read more »

Satellite on planet background
Investing Articles

Is this the best bargain in the FTSE 250 right now?

This FTSE 250 defence stock is a world leader in testing and evaluation technology for military use and has seen…

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

How would I start planning my Stocks and Shares ISA for 2025? With this super-solid growth stock

I can’t think of a better way to prepare for a new year than opening a fresh Stock and Shares…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Down 26% to just £4, Glencore’s share price looks cheap to me right now

Market pessimism over China’s economic growth has helped push Glencore’s share price down but I think this is overdone, leaving…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

Just released: the 3 best growth-focused stocks to consider buying in November [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Why now could be the time to get ready for a stock market crash

Both the FTSE 100 and the S&P 500 climbed after the US election results. But Stephen Wright thinks now is…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

A UK share and an ETF that could soar following Trump’s election win

Donald Trump's White House return poses huge uncertainty for the global economy. But this UK share and ETF could gain…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

2 FTSE stocks that demonstrate the best (and worst) of the AIM market

Our writer looks at the performance of two very different FTSE stocks that highlights the pros and cons of investing…

Read more »